Exiris provides contract research services and collaborative development agreements using its innovative technology platforms: CSC Platform, Target ID, Drug Conjugate Platform, Custom human mAb production, Biomarker discovery and Drug development.
Exiris makes use of several platform technologies for target identification and validation. In addition, Exiris is developing its own antibody and drug conjugate technologies:
Human skin equivalents
- Discover skin biomarkers in human skin equivalent cultures
Drug Development Services
The Exiris team has specific expertise in several areas of cancer drug discovery and has a large toolbox available for the development of histone deacetylase inhibitors and compounds targeting the Hedgehog pathway.
In addition we offer the following services:
- Medium scale compound testing
- Set up and validation of enzyme assays
- Development of cell based reporter assays
- Selection of stable transfected cell clones
Exiris has a wide network of academic relationships through which we can provide preclinical support to clients and partners by providing specific pathway expertise, preclinical in vitro and in vivo models, access to primary, patient-derived samples and bioinformatics support.
Just inquire. We will be happy to discuss your projects with you and come up with highly flexible solutions, specifically tailored to your needs.